相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT
Kimball A. Johnson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
Samuel Lederman et al.
LANCET (2023)
Fezolinetant in the treatment of vasomotor symptoms associated with menopause
Herman Depypere et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
Graeme L. Fraser et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2020)
Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial
Herman Depypere et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Neurokinin 3 Receptor Antagonism: A Novel Treatment for Menopausal Hot Flushes
Manish Modi et al.
NEUROENDOCRINOLOGY (2019)
The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN)
Samar R. El Khoudary et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2019)
Glutamatergic Neurokinin 3 Receptor Neurons in the Median Preoptic Nucleus Modulate Heat-Defense Pathways in Female Mice
Sally J. Krajewski-Hall et al.
ENDOCRINOLOGY (2019)